Skip to Main Content

Good morning. Elizabeth Cooney sitting in for Ed Silverman, who is covering the J.P. Morgan Healthcare Conference with five STAT colleagues in San Francisco. We have snow flurries here at Boston HQ after yesterday’s temps in the 70s, so you’re not missing a thing, @pharmalot, @adamfeuerstein@damiangarde@rebeccadrobbins@erbrod, and @matthewherper. Meanwhile, we’ve got news for you.

AstraZeneca (AZN) said Monday that it would stop a large clinical study of a fish-oil-derived heart drug, Epanova, after an independent committee concluded it was “unlikely to demonstrate a benefit to patients,” STAT reports. The news removes the most likely competitor for Amarin Pharmaceuticals’ (AMRN) Vascepa, the first heart drug derived from fish oil to be approved to reduce the risk of heart attacks, strokes, and hospitalizations due to heart problems in patients with high levels of triglycerides.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!